Dallas, Texas (PRWEB) October 05, 2013
Targeting kinases have been on the agenda of most drug developers/researchers as they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer. Resistance to existing therapies develops as cancer cells bypass these efforts and there remains an evergreen search for new targets to meet these challenges. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $ 10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years.
Key Points Discussed in the Report Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors – http://www.reportsnreports.com/reports/219484-drivers-of-ma-in-2013-2016-pi3ks-and-btk-inhibitors.html
1. Drugs in the pipeline